Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.32 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL6986956 | 0.98 | GRM4 (0.38) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| SCHEMBL6501033 | 0.78 | GRM4 (0.39) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| SCHEMBL1578942 | 0.78 | KDM4E (0.53) | GRM4SORT1KDM4ELMNAKDM5A | |
| SCHEMBL7068952 | 0.78 | ALDH1A1 (0.33) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| SCHEMBL27801110 | 0.77 | KDM4E (0.52) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| Ammonia Solution, Strong SCHEMBL27766041 | 0.77 | KDM4E (0.52) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| SCHEMBL6989840 | 0.75 | CYP1A2 (0.37) | GRM4KDM4ELMNAPIK3C3ALDH1A1 | |
| SCHEMBL882664 | 0.74 | ALDH1A1 (0.47) | GRM4SORT1KDM4ELMNAPIK3C3 | |
| SCHEMBL2829062 | 0.72 | ADORA3 (0.41) | SORT1KDM4ELMNAKDM5AJMJD1C | |
| SCHEMBL14192611 | 0.72 | SORT1 (0.39) | GRM4SORT1KDM4ELMNAPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | GRM4 1024/4885SORT1 3810/4885KDM4E 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.